The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function

NeuroImage

Volumn 50, Issue 2, 2010, Pages 524-531

  Egerton, Alice ^a,b,c   Demjaha, Arsime ^a,c   McGuire, Philip ^c   Mehta, Mitul A ^a,b,c   Howes, Oliver D ^a,b,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

18F DOPA; Dopamine; Extrastriatal; Longitudinal; Parkinson's disease; Positron emission tomography; Reliability; Reproducibility; Schizophrenia; Striatum

Indexed keywords

6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DOPA; DOPAMINE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; ASSOCIATION CORTEX; BRAIN LEVEL; BRAIN MAPPING; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION COEFFICIENT; DOPAMINERGIC ACTIVITY; EXPERIMENTAL DESIGN; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PUTAMEN; REPRODUCIBILITY; SENSORIMOTOR CORTEX; TEST RETEST RELIABILITY; THALAMUS; TISSUE DISTRIBUTION; BRAIN; METABOLISM; SCINTISCANNING; SYNAPTOSOME;

ADULT; BRAIN; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 77952300776     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.12.058     Document Type: Article

References (53)

1. Bose, S.K., Turkheimer, F.E., Howes, O.D., Mehta, M.A., Cunliffe, R., Stokes, P.R., Grasby, P.M., 2008. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr. Res. 106, 148-155.
2. Bouchard, S., Bousquet, C., Roberge, A.G., 1981. Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat. J. Neurochem. 37, 781-787.
3. Brooks, D.J., 2003a. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann. Neurol. 53 (Suppl. 3), S110-S118.
4. Brooks, D.J., 2003b. PET studies on the function of dopamine in health and Parkinson's disease. Ann. N. Y. Acad. Sci 991, 22-35.
5. Brooks, D.J., Frey, K.A., Marek, K.L., Oakes, D., Paty, D., Prentice, R., Shults, C.W., Stoessl, A. J., 2003. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol. 184 (Suppl. 1), S68-S79.
6. Brooks, D.J., Piccini, P., 2006. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol. Psychiatry 59, 908-918.
7. Bruck, A., Portin, R., Lindell, A., Laihinen, A., Bergman, J., Haaparanta, M., Solin, O., Rinne, J.O., 2001. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci. Lett. 311, 81-84.
8. Caceres, A., Hall, D.L., Zelaya, F.O., Williams, S.C., Mehta, M.A., 2009. Measuring fMRI reliability with the intra-class correlation coefficient. Neuroimage 45, 758-768.
9. Cropley, V.L., Fujita, M., Bara-Jimenez, W., Brown, A.K., Zhang, X.Y., Sangare, J., Herscovitch, P., Pike, V.W., Hallett, M., Nathan, P.J., Innis, R.B., 2008. Pre- and post- synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res. 163, 171-182.
10. Cumming, P., Leger, G.C., Kuwabara, H., Gjedde, A., 1993. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. J. Cereb. Blood Flow Metab. 13, 668-675.
11. Cumming, P., Deep, P., Rousset, O., Evans, A., Gjedde, A., 1997. On the rate of decarboxylation of dopa to dopamine in the living mammillian brain. Ann. N. Y. Acad. Sci. 835, 274-308.
12. Danielsen, E.H., Smith, D., Hermansen, F., Gjedde, A., Cumming, P., 2001. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41, 172-175.
13. Drevets, W.C., Gautier, C., Price, J.C., Kupfer, D.J., Kinahan, P.E., Grace, A.A., Price, J.L., Mathis, C.A., 2001. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol. Psychiatry 49, 81-96.
14. Dupont, W.D., Plummer Jr, W.D., 1990. Power and sample size calculations. A review and computer program. Control Clin. Trials 11, 116-128.
15. Eshuis, S.A., Jager, P.L., Maguire, R.P., Jonkman, S., Dierckx, R.A., Leenders, K.L., 2009. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur. J. Nucl. Med. Mol. Imaging 36, 454-462.
16. Grunder, G., Vernaleken, I., Muller, M.J., Davids, E., Heydari, N., Buchholz, H.G., Bartenstein, P., Munk, O.L., Stoeter, P., Wong, D.F., Gjedde, A., Cumming, P., 2003. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28, 787-794.
17. Guttman, M., Leger, G., Reches, A., Evans, A., Kuwabara, H., Cedarbaum, J.M., Gjedde, A., 1993. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord. 8, 298-304.
18. Hammers, A., Allom, R., Koepp, M.J., Free, S.L., Myers, R., Lemieux, L., Mitchell, T.N., Brooks, D.J., Duncan, J.S., 2003. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 19, 224-247.
19. Hartvig, P., Agren, H., Reibring, L., Tedroff, J., Bjurling, P., Kihlberg, T., Langstrom, B., 1991. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography. J. Neural. Transm. Gen. Sect. 86, 25-41.
20. Heiss, W.D., Hilker, R., 2004. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur. J. Neurol. 11, 5-12.
21. Hirvonen, J., Aalto, S., Lumme, V., Nagren, K., Kajander, J., Vilkman, H., Hagelberg, N., Oikonen, V., Hietala, J., 2003. Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nucl. Med. Commun. 24, 1207-1214.
22. Hoffman, J.M., Melega, W.P., Hawk, T.C., Grafton, S.C., Luxen, A., Mahoney, D.K., Barrio, J.R., Huang, S.C., Mazziotta, J.C., Phelps, M.E., 1992. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography. J. Nucl. Med. 33, 1472-1477.
23. Hoshi, H., Kuwabara, H., Leger, G., Cumming, P., Guttman, M., Gjedde, A., 1993. 6-[18F] fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J. Cereb. Blood Flow Metab. 13, 57-69.
24. Howes, O.D., Montgomery, A.J., Asselin, M.C., Murray, R.M., Grasby, P.M., McGuire, P.K., 2007. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry Suppl. 51, s13-s18.
25. Howes, O.D., Montgomery, A.J., Asselin, M.C., Murray, R.M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., McGuire, P.K., Grasby, P.M., 2009. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 66, 13-20.
26. Jokinen, P., Helenius, H., Rauhala, E., Bruck, A., Eskola, O., Rinne, J.O., 2009. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J. Nucl. Med. 50, 893-899.
27. Kumakura, Y., Vernaleken, I., Buchholz, H.G., Borghammer, P., Danielsen, E., Grunder, G., Heinz, A., Bartenstein, P., Cumming, P., 2008. Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiol. Aging. doi:10.1016/j.neurobiolaging.2008.05.005.
28. Lindemann, L., Hoener, M.C., 2005. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci. 26, 274-281.
29. Martinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D.R., Huang, Y., Cooper, T., Kegeles, L., Zarahn, E., bi-Dargham, A., Haber, S.N., Laruelle, M., 2003. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab. 23, 285-300.
30. Mawlawi, O., Martinez, D., Slifstein, M., Broft, A., Chatterjee, R., Hwang, D.R., Huang, Y., Simpson, N., Ngo, K., Van Heertum, R., Laruelle, M., 2001. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 21, 1034-1057.
31. McGowan, S., Lawrence, A.D., Sales, T., Quested, D., Grasby, P., 2004. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch. Gen. Psychiatry 61, 134-142.
32. McGraw, K.O., Wong, S.P., 1996. Forming inferences about some intraclass correlation coefficients. Psychol. Methods 1, 30-46.
33. Montgomery, A.J., Thielemans, K., Mehta, M.A., Turkheimer, F., Mustafovic, S., Grasby, P.M., 2006. Correction of head movement on PET studies: comparison of methods. J. Nucl. Med. 47, 1936-1944.
34. Moore, R.Y., Whone, A.L., McGowan, S., Brooks, D.J., 2003. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res. 982, 137-145.
35. Moore, R.Y., Whone, A.L., Brooks, D.J., 2008. Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol. Dis. 29, 381-390.
36. Nakamura, T., Dhawan, V., Chaly, T., Fukuda, M., Ma, Y., Breeze, R., Greene, P., Fahn, S., Freed, C., Eidelberg, D., 2001. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann. Neurol. 50, 181-187.
37. Nozaki, S., Kato, M., Takano, H., Ito, H., Takahashi, H., Arakawa, R., Okumura, M., Fujimura, Y., Matsumoto, R., Ota, M., Takano, A., Otsuka, A., Yasuno, F., Okubo, Y., Kashima, H., Suhara, T., 2009. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr. Res. 108, 78-84.
38. Ota, M., Yasuno, F., Ito, H., Seki, C., Nozaki, S., Asada, T., Suhara, T., 2006. Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA. Life Sci. 79, 730-736.
39. Patlak, C.S., Blasberg, R.G., 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5, 584-590.
40. Piccini, P., Pavese, N., Hagell, P., Reimer, J., Bjorklund, A., Oertel, W.H., Quinn, N.P., Brooks, D.J., Lindvall, O., 2005. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128, 2977-2986.
41. Sawle, G.V., Burn, D.J., Morrish, P.K., Lammertsma, A.A., Snow, B.J., Luthra, S., Osman, S., Brooks, D.J., 1994. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 44, 1292-1297.
42. Shrout, P.E., Fleiss, J.L., 1979. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 86, 420-428.
43. Snow, B.J., Tooyama, I., McGeer, E.G., Yamada, T., Calne, D.B., Takahashi, H., Kimura, H., 1993. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34, 324-330.
44. Studholme, C., Hill, D.L., Hawkes, D.J., 1996. Automated 3-D registration of MR and CT images of the head. Med. Image Anal. 1, 163-175.
45. Tedroff, J., Torstenson, R., Hartvig, P., Sonesson, C., Waters, N., Carlsson, A., Neu, H., Fasth, K.J., Langstrom, B., 1998. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tonedependent normalization of striatal dopaminergic activity. Synapse 28, 280-287.
46. Torstenson, R., Hartvig, P., Langstrom, B., Bastami, S., Antoni, G., Tedroff, J., 1998. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 37, 989-995.
47. Turkheimer, F.E., Brett, M., Visvikis, D., Cunningham, V.J., 1999. Multiresolution analysis of emission tomography images in the wavelet domain. J. Cereb. Blood Flow Metab. 19, 1189-1208.
48. Vernaleken, I., Buchholz, H.G., Kumakura, Y., Siessmeier, T., Stoeter, P., Bartenstein, P., Cumming, P., Grunder, G., 2007. 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum. Brain Mapp. 28, 931-939.
49. Vernaleken, I., Kumakura, Y., Cumming, P., Buchholz, H.G., Siessmeier, T., Stoeter, P., Muller, M.J., Bartenstein, P., Grunder, G., 2006. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30, 1332-1339.
50. Vernaleken, I., Kumakura, Y., Buchholz, H.G., Siessmeier, T., Hilgers, R.D., Bartenstein, P., Cumming, P., Grunder, G., 2008. Baseline [(18)F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. Neuroimage 40, 1222-1231.
51. Vingerhoets, F.J., Snow, B.J., Schulzer, M., Morrison, S., Ruth, T.J., Holden, J.E., Cooper, S., Calne, D.B., 1994. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J. Nucl. Med. 35, 18-24.
52. Vingerhoets, F.J., Schulzer, M., Ruth, T.J., Holden, J.E., Snow, B.J., 1996. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-DOPA PET in Parkinson's disease. J. Nucl. Med. 37, 421-426.
53. Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias, C., Lang, A.E., Rascol, O., Ribeiro, M.J., Remy, P., Poewe, W.H., Hauser, R.A., Brooks, D.J., 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54, 93-101.